Stephen P. Richman

2.4k total citations
67 papers, 1.9k citations indexed

About

Stephen P. Richman is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Stephen P. Richman has authored 67 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 15 papers in Surgery and 13 papers in Molecular Biology. Recurrent topics in Stephen P. Richman's work include Cancer Immunotherapy and Biomarkers (11 papers), Cancer Treatment and Pharmacology (9 papers) and Lung Cancer Research Studies (8 papers). Stephen P. Richman is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Cancer Treatment and Pharmacology (9 papers) and Lung Cancer Research Studies (8 papers). Stephen P. Richman collaborates with scholars based in United States, United Kingdom and Chile. Stephen P. Richman's co-authors include Judith Hurley, Tito R. Mendoza, Charles S. Cleeland, Guadalupe R. Palos, Vicente Valero, Karen O. Anderson, Jordan U. Gutterman, Richard Payne, Ibrahima Gning and Lynn G. Feun and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Stephen P. Richman

67 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephen P. Richman United States 21 1.1k 385 345 325 294 67 1.9k
Martin Levitt Canada 18 847 0.8× 266 0.7× 59 0.2× 312 1.0× 315 1.1× 36 1.8k
W.J. Hoskins United States 24 876 0.8× 354 0.9× 81 0.2× 365 1.1× 244 0.8× 50 3.0k
Barry S. Berman United States 9 765 0.7× 302 0.8× 128 0.4× 234 0.7× 281 1.0× 12 1.3k
Rajnish K. Gupta United States 22 519 0.5× 183 0.5× 104 0.3× 233 0.7× 130 0.4× 89 1.9k
Young Seon Hong South Korea 24 790 0.7× 208 0.5× 39 0.1× 579 1.8× 227 0.8× 75 1.8k
David N. Korones United States 25 249 0.2× 403 1.0× 67 0.2× 242 0.7× 243 0.8× 88 1.9k
Giovanni Rosti Italy 29 804 0.8× 555 1.4× 38 0.1× 267 0.8× 247 0.8× 127 2.7k
Alexandra Easson Canada 22 730 0.7× 262 0.7× 44 0.1× 239 0.7× 116 0.4× 65 1.8k
John D. Cramer United States 23 647 0.6× 502 1.3× 213 0.6× 217 0.7× 54 0.2× 68 2.1k
Charles L. M. Olweny Uganda 20 502 0.5× 207 0.5× 30 0.1× 291 0.9× 145 0.5× 55 1.3k

Countries citing papers authored by Stephen P. Richman

Since Specialization
Citations

This map shows the geographic impact of Stephen P. Richman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen P. Richman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen P. Richman more than expected).

Fields of papers citing papers by Stephen P. Richman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen P. Richman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen P. Richman. The network helps show where Stephen P. Richman may publish in the future.

Co-authorship network of co-authors of Stephen P. Richman

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen P. Richman. A scholar is included among the top collaborators of Stephen P. Richman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen P. Richman. Stephen P. Richman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cleeland, Charles S., Tito R. Mendoza, Xin Shelley Wang, et al.. (2011). Levels of Symptom Burden During Chemotherapy for Advanced Lung Cancer: Differences Between Public Hospitals and a Tertiary Cancer Center. Journal of Clinical Oncology. 29(21). 2859–2865. 37 indexed citations
2.
Lobo, Christopher, Gilberto Lopes, Aurelio Castrellon, et al.. (2010). Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment. 123(2). 427–435. 68 indexed citations
3.
Anderson, Karen O., Stephen P. Richman, Judith Hurley, et al.. (2002). Cancer pain management among underserved minority outpatients. Cancer. 94(8). 2295–2304. 188 indexed citations
4.
Lee, Yong J., Judith Hurley, Carolyn Mies, et al.. (1998). A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma. Cancer. 82(3). 503–511. 34 indexed citations
5.
Whitehead, Robert P., Michael Wolf, Dilip L. Solanki, et al.. (1995). A Phase II Trial of Continuous-Infusion Recombinant Interleukin-2 in Patients with Advanced Renal Cell Carcinoma. Journal of Immunotherapy. 18(2). 104–114. 6 indexed citations
6.
7.
Taylor, Sarah A., Jacqueline Benedetti, David Schuller, et al.. (1993). Phase II trial of piroxantrone in patients with recurrent and metastatic squamous cell carcinoma of the head and neck. Investigational New Drugs. 11(2-3). 227–229. 2 indexed citations
8.
Gucalp, Rasim, Paul S. Ritch, P H Wiernik, et al.. (1992). Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.. Journal of Clinical Oncology. 10(1). 134–142. 114 indexed citations
9.
Ardalan, Bach, K. Rajender Reddy, Pasquale Benedetto, et al.. (1992). Phase I study of high dose 5-fluorouracil and high dose leucovorin with low dose phosphonacetyl-l-aspartic acid in patients with advanced malignancies. International Journal of Radiation Oncology*Biology*Physics. 22(3). 511–514. 17 indexed citations
10.
11.
Ardalan, Bach, K. S. Sridhar, Pasquale Benedetto, et al.. (1991). A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. Cancer. 68(6). 1242–1246. 12 indexed citations
12.
Sridhar, Kasi S., William Raub, Robert Duncan, Susan G. Hilsenbeck, & Stephen P. Richman. (1991). Lung Carcinoma in 1,336 Patients. American Journal of Clinical Oncology. 14(6). 496–508. 17 indexed citations
13.
Sridhar, Kasi S., T. S. Anantha Samy, Ram P. Agarwal, et al.. (1990). A phase i study of 4′-0-tetrahydropyranyladriamycin: Clinical pharmacology and pharmacokinetics. Cancer. 66(10). 2082–2091. 16 indexed citations
14.
Blumenreich, Martin S., et al.. (1988). A Phase I Trial of Chlorambucil Administered in Short Pulses in Patients with Advanced Malignancies. Cancer Investigation. 6(4). 371–375. 5 indexed citations
15.
Blumenreich, Martin S., Thomas Woodcock, Patrick S. Gentile, et al.. (1987). High-dose cisplatin and vinblastine infusion with or without radiation therapy in patients with advanced non-small-cell lung cancer.. Journal of Clinical Oncology. 5(11). 1725–1730. 11 indexed citations
16.
Blumenreich, Martin S., et al.. (1985). A phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies. Cancer. 56(2). 256–258. 2 indexed citations
17.
Barlogie, Bart, et al.. (1982). Medulloblastoma and neuroblastoma in adults.. PubMed. 25(4). 94–9. 5 indexed citations
18.
Allegra, Joseph C., Thomas Woodcock, & Stephen P. Richman. (1981). A phase II evaluation of tamoxifen, premarin, methotrexate (MTX) and 5-fluorouracil (5-FU) in stage IV breast cancer. 2 indexed citations
19.
Schwarz, Max, Jordan U. Gutterman, Evan M. Hersh, Stephen P. Richman, & Giora M. Mavligit. (1977). Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions. World Journal of Surgery. 1(5). 555–579. 2 indexed citations
20.
Gutterman, Jordan U., et al.. (1975). Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the future.. PubMed. 2(2). 155–74. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin Levitt Breakdown of academic impact, for papers by W.J. Hoskins Breakdown of academic impact, for papers by Barry S. Berman Breakdown of academic impact, for papers by Rajnish K. Gupta Breakdown of academic impact, for papers by Young Seon Hong Breakdown of academic impact, for papers by David N. Korones Breakdown of academic impact, for papers by Giovanni Rosti Breakdown of academic impact, for papers by Alexandra Easson Breakdown of academic impact, for papers by John D. Cramer Breakdown of academic impact, for papers by Charles L. M. Olweny
Rankless by CCL
2026